ID: ALA1950799

Max Phase: Preclinical

Molecular Formula: C20H18N2O7

Molecular Weight: 398.37

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(O)c1ccc(-c2ccc(C(=O)N3CCN[C@H](C(=O)O)[C@@H]3C(=O)O)cc2)cc1

Standard InChI:  InChI=1S/C20H18N2O7/c23-17(22-10-9-21-15(19(26)27)16(22)20(28)29)13-5-1-11(2-6-13)12-3-7-14(8-4-12)18(24)25/h1-8,15-16,21H,9-10H2,(H,24,25)(H,26,27)(H,28,29)/t15-,16+/m0/s1

Standard InChI Key:  QRJSONBPAALFIP-JKSUJKDBSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 398.37

Molecular Weight (Monoisotopic): 398.1114

AlogP: 1.00

#Rotatable Bonds: 5

Polar Surface Area: 144.24

Molecular Species: ACID

HBA: 5

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 2.59

CX Basic pKa: 7.81

CX LogP: -0.87

CX LogD: -7.37

Aromatic Rings: 2

Heavy Atoms: 29

QED Weighted: 0.58

Np Likeness Score: -0.23

References

1. Irvine MW, Costa BM, Dlaboga D, Culley GR, Hulse R, Scholefield CL, Atlason P, Fang G, Eaves R, Morley R, Mayo-Martin MB, Amici M, Bortolotto ZA, Donaldson L, Collingridge GL, Molnár E, Monaghan DT, Jane DE..  (2012)  Piperazine-2,3-dicarboxylic acid derivatives as dual antagonists of NMDA and GluK1-containing kainate receptors.,  55  (1): [PMID:22111545] [10.1021/jm201230z]

Source

Source(1):

• Scientific Literature